Invesco Biotechnology & Genome ETF

United Therapeutics CFO James Edmonds Sells $5.64M in Stock

Insightec Partners with Edison Science to Deploy Kosmos AI Platform for Accelerated Drug Development

ProShare Advisors Increases Gilead Stake by 39.1% in Q4, Total Holdings Reach 2.2 Million Shares

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

United Therapeutics Announces Tyvaso Met Primary Endpoint in IPF Phase 3 Trial, Plans FDA Submission for New Indication

Truist Financial Cuts Regeneron Price Target, Sending Shares Gap Down

Regeneron's fianlimab combination fails Phase 3, shares plunge over 11%

Regeneron Partners with Parabilis for $125M Deal to Advance Antibody Conjugates

TD Cowen Analyst Thome Reaffirms Buy Rating on United Therapeutics with $675 Target

United Therapeutics announces Phase III trial success for ralinepag, plans FDA submission in late 2026

Gilead Sciences Focuses on HIV Growth and Expands Oncology and Inflammation Pipeline via Acquisitions

United Therapeutics CFO James Edgemond Sells 10,000 Shares for $5.74 Million

Regeneron Provides Update on Phase 3 Trial of Fianlimab Combination for Melanoma

Combination Therapy Approved by FDA to Launch Pig-Derived UHeart Xenotransplant Clinical Trial

Oppenheimer Raises Biogen Price Target to $300, Maintains Outperform Rating

Gilead Sciences Prices $3 Billion Senior Unsecured Bond Offering

TD Cowen Reaffirms Buy Rating on Biogen with $215 Price Target

Biogen Finalizes Acquisition Agreements with Apellis: Establishes SYFOVRE Milestone CVR and Secures $2 Billion Loan

Biogen Advances Alzheimer's Drug to Late Trials Despite Mid-Stage Failure, Shares Jump 6%

Biogen Announces Positive Phase 2 Results for Ionis Partner Drug Diranersen in Alzheimer's Disease

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Pinned News

置顶新闻

Agilent and Singapore's NATi Partner to Advance Lipid-Conjugated Oligonucleotide Research

SBIO

Agilent Technologies has partnered with Singapore's Nucleic Acid Therapeutics Initiative (NATi) to enhance lipid-conjugated oligonucleotide research. This two-year collaboration aims to develop new delivery platforms for oligonucleotides, expanding therapeutic applications beyond liver tissues. The partnership combines NATi's expertise with Agilent's advanced analytical technologies, supporting the growth of the oligo therapeutics market, projected to reach $18 billion by 2030. The agreement also includes training and access to Agilent's Global Solution Development Center in Singapore.

PR Newswire

Agilent Tech

ALPS Medical Breakthrough

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

CODX

LABU

Co-Diagnostics has initiated a $3 million private placement, selling 1,647,447 common shares and pre-funded warrants to institutional investors. The offering includes warrants for an additional 3,294,894 shares at an effective price of $1.82 per share. The warrants have an exercise price of $1.57, are immediately exercisable, and expire in five years. The closing is anticipated around May 21, 2026, pending customary conditions.

PUBT

Co-Diagnostics

SPDR S&P Health Equip

Direxion S&P Biotech Bull 3X

iShares US Medical Devices

Co-Diagnostics prices USD 3 million private placement at market under Nasdaq rules

ILMN

Illumina's Q1 earnings call revealed a positive outlook with a revenue of $1.09 billion, exceeding guidance. The company reported strong demand for NovaSeq X and raised its 2026 revenue forecast. Despite challenges in research spending and inflation, Illumina's gross margin improved to 68.2%, and EPS rose to $1.15. The firm also announced a $1.5 billion buyback program and highlighted ongoing product innovations. However, research consumables faced declines, and supply constraints impacted NovaSeq X placements.

Tip Ranks

Illumina

SOMALOGIC INC

Illumina Earnings Call Signals Confident Clinical Pivot

IMNN

ARKG

IBBQ

Imunon, Inc. held its Q1 earnings call, highlighting clinical advancements with IMNN-001, which shows promising survival data. However, management expressed concerns over rising cash burn and capital market challenges. The pivotal OVATION III trial is underway, with a focus on minimizing shareholder dilution through strategic financing. Despite strong investigator interest, the lengthy timeline for data and regulatory submission poses risks for investors. The company aims to present detailed efficacy data at an upcoming R&D Day in 2026.

Imunon

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

iShares US Pharma

Imunon Earnings Call Balances Breakthroughs and Cash Strain

RNXT

RenovoRx, Inc. reported record Q1 2026 revenue of $563,000, marking a 136% sequential growth. The company highlighted strong gross margins of 85.1% and an expanding commercial footprint with 16 active cancer centers. A pivotal Phase III trial is nearing full enrollment, and recent financing extends its cash runway into 2027. Despite impressive growth, management acknowledged execution risks and the need for consistent center conversions to sustain revenue growth. The company maintains a full-year revenue outlook of $3.0 million to $4.0 million.

RenovoRx

iShares Global Healthcare

VG Health

RenovoRx Earnings Call Signals Commercial Inflection

CBUS

Cibus, Inc. reported its Q1 earnings, raising $37 million to extend its cash runway to late Q1 2027. The company noted improved cost control, with operating expenses down nearly $8 million, but acknowledged ongoing financial risks and uncertainty in revenue generation. Key developments include progress in its rice program in LATAM and advancements in sustainable ingredients. However, the U.S. rice launch has been delayed to 2029, and profitability remains distant with a net loss of $21.2 million.

Cibus

Cibus Earnings Call: Cash Extended, Execution Critical

588130

159892

510660

Antengene has appointed Bing Hou as chief scientific officer, effective May 19, 2026. He will oversee drug discovery and R&D efforts, reporting to CEO Jay Mei. Hou, who joined Antengene in 2019, previously served as vice president of discovery science. He holds a PhD in biomedicine and has over 40 patent applications.

ChinaAMC SSE STAR Biology and Medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Penghua CSI HK Connect Health Care Composite ETF

Tianhong CNI BIOMEDICINE ETF

E Fund CSI 300 Health Care ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Guotai CSI Bio-medicine ETF

E Fund CSI Biotechnology Theme ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

BlackRock, Inc.

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

ANTENGENE-B

Antengene appoints Bing Hou as chief scientific officer

Antengene Corporation has appointed Dr. Bing Hou as Chief Scientific Officer to enhance its R&D strategy and advance its next-generation therapeutic pipeline. Dr. Hou, who has been with Antengene since 2019, will lead efforts in Drug Discovery and Translational Medicine. His leadership is expected to strengthen the company's proprietary platforms, including the AnTenGager® T-cell engager platform, and support the development of innovative therapies for autoimmune diseases and cancers.

ChinaAMC CSI Biotechnology Theme ETF

Proshares UltraShort Nasdaq Biotech

UCB S.A.

Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline

BBIO

BridgeBio Pharma received a Hold rating and price target from Citi analyst today.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In addition to Citi, BridgeBio Pharma also received a Hold from J.P. Morgan’s Eric Joseph in a report issued today. However, on May 13, Bank of America Securities reiterated a Buy rating on BridgeBio Pharma (NASDAQ: BBIO).

Bridgebio Pharma

Direxion S&P Biotech Bear 3X

Citigroup

JPMorgan Chase

Bank of America

CITIGROUP INC 6.250 NON CUM SER II PFD WI

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

BridgeBio Pharma (BBIO) Gets a Hold from Citi

ERAS

RVMD

Kirby McInerney LLP is investigating potential claims against Erasca, Inc. (NASDAQ:ERAS) regarding possible violations of federal securities laws following a patent infringement allegation from Revolution Medicines. This news caused Erasca's stock to drop by approximately 48%. No lawsuit has been filed yet, and the investigation is ongoing. Investors with information or interest are encouraged to contact the law firm.

MorningStar

Erasca

Revolution Medicines

REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM)

ERAS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Erasca, Inc.

VXRT

Vaxart (VXRT) has urged shareholders to support its board nominees amid a proxy contest, emphasizing the importance of experienced leadership for its oral vaccine platform. The company reported progress in its COVID-19 trial and other vaccine programs, while detailing financial measures to extend its cash runway. Analysts rate VXRT as a Buy with a $4.00 price target, though execution risks remain. Vaxart focuses on developing oral vaccines for infectious diseases, positioning itself against traditional injectable products.

Vaxart

Dynavax Tech

Vaxart Urges Shareholder Support Amid Proxy Contest, Updates Pipeline

Invesco Biotechnology & Genome ETF(PBE.US)